By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New drug approved for use against C diff in Wales

A new antibiotic treatment for Clostridium difficile has been accepted for restricted use by the NHS in Wales.

The All Wales Medicines Strategy Group, which advises NHS Wales on prescribing new treatments, has approved fidaxomicin (Dificlir) for the treatment of C difficile in adults with severe or recurrent cases of the infection.

Fidaxomicin, which is a first-in-class antibiotic manufactured by Astellas Pharma, was shown in trials to be non-inferior to vancomycin.

It demonstrated a similar efficacy and tolerability, according to Astellas, but more than halved the rate of recurrence in patients with C difficile, compared to vancomycin (12.7% versus 26.9%).

The European Commission licensed fidaxomicin tablets for the treatment of adults with C difficile in December 2011 and the drug was launched in the UK in June.

Between April 2011 and March 2012 the healthcare associated infection affected over 2,100 people in Wales and was associated with 236 deaths during 2011.

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!